YUCAIPA, Calif., May 19, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a medical device manufacturer with an emerging new medical product line for the $4 billion U.S. and $8 billion global respiratory market, today announced their success from MedTrade-Spring last week in Las Vegas, NV.
The MedTrade theme was focused on home health care and home medical equipment (HME). As Ingen's product was a featured display in the New Product Pavilion, hundreds of professionals came by the Ingen booth to discuss distribution opportunities, purchases and demonstration of the new Smart Nasal Cannula with Oxyview technology.
MedTrade is the largest home medical equipment event in the western US, where top names in the HME industry and new exhibitors, such as Ingen, bring new products that serve patients better. Industry-leading manufacturers with years of service to HME providers roll out the best of the best at Medtrade-Spring. Ingen networked with distributors, exhibitors, homecare providers, and many unique investors during the conference from May10th-13th.
The company expects a massive national and global distribution program over the next 2 months as it prepares back-orders for export sales.
"According to many of the professionals who came by the Ingen booth, the Smart Nasal Cannula had the most 'sex-appeal' of any product at the MedTrade exhibit. Ingen Technologies is pleased to have been labeled as a 'new product' exhibitor in Las Vegas last week during the MedTrade conference. Staff attended the booth and demonstrated our product to hundreds of professionals. We attended scheduled meetings with distributors and home medical equipment manufacturers who greatly expressed interest. We have quotes out for $400,000 in product, and will update shareholders on product sales over the next few weeks as results come in. The show was so successful; we registered for the MedTrade-Fall conference scheduled in Atlanta-Georgia on November 15, 2010," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
http://www.smartnasalcannula.com/
http://www.ingenpulseoximeter.com/
About Ingen:
Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. For example, when we say that we have quotes out for $400,000 in product, and will update shareholders on product sales over the next few weeks, we are using forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.